Gregory W. Roloff, MD, on Further Investigation With Sequencing and CAR T in B-ALL
The chief hematology/oncology fellow at University of Chicago discussed further research his center is working on with cell therapy in B-cell acute lymphoblastic leukemia.
“One question that we're puzzled by but we're trying to investigate, with regard to sequencing of therapies, is, it looks like patients who receive prior inotuzumab do a little bit worse, compared to those who do not. And we think it's probably a marker of the type of patients in whom you're using inotuzumab who have more gross and bulky disease from the get go.”
Brexucabtagene autoleucel (Tecartus; Kite) demonstrated a 90% complete response rate and 82% minimal residual disease negativity rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), according to new, real-world data from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) study.
These data were presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California, by Gregory Roloff, MD, chief hematology/oncology fellow, University of Chicago.
CGTLive spoke with Roloff to learn more about other research he and his group are involved in, and what topics he was most interested in being featured at the 2023 ASH Meeting. Other research out of his group included presentations on bridging therapy, toxicities, and social determinants of health. Of these items of interest, he touched on Claire Roddie, MD, PhD’s presentation on the phase 1 ALLCAR19 trial (NCT02935257) and the phase 1b/2 FELIX trial (NCT04404660) of obecabtagene autoleucel (obe-cel) CAR T-cell therapy in patients with relapsed/refractory B-ALL.
Click here to view more coverage of the 2023 ASH meeting.
